nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—colon cancer	0.71	1	CbGaD
Amantadine—Visual disturbance—Irinotecan—colon cancer	0.00155	0.00738	CcSEcCtD
Amantadine—Amnesia—Fluorouracil—colon cancer	0.0015	0.00713	CcSEcCtD
Amantadine—Osteoarthritis—Irinotecan—colon cancer	0.00147	0.007	CcSEcCtD
Amantadine—Paralysis—Methotrexate—colon cancer	0.00145	0.00691	CcSEcCtD
Amantadine—Cardiac failure—Fluorouracil—colon cancer	0.00144	0.00687	CcSEcCtD
Amantadine—Lethargy—Fluorouracil—colon cancer	0.00144	0.00684	CcSEcCtD
Amantadine—Urinary retention—Vincristine—colon cancer	0.00143	0.00683	CcSEcCtD
Amantadine—Cardiac arrest—Vincristine—colon cancer	0.00143	0.00683	CcSEcCtD
Amantadine—Dysarthria—Capecitabine—colon cancer	0.00143	0.00682	CcSEcCtD
Amantadine—Ataxia—Vincristine—colon cancer	0.00142	0.00675	CcSEcCtD
Amantadine—Osteoarthritis—Fluorouracil—colon cancer	0.00141	0.0067	CcSEcCtD
Amantadine—Cardiac arrest—Irinotecan—colon cancer	0.0014	0.00665	CcSEcCtD
Amantadine—Gait disturbance—Capecitabine—colon cancer	0.00139	0.00661	CcSEcCtD
Amantadine—Stupor—Methotrexate—colon cancer	0.00135	0.00643	CcSEcCtD
Amantadine—Irritability—Fluorouracil—colon cancer	0.00134	0.0064	CcSEcCtD
Amantadine—Orthostatic hypotension—Irinotecan—colon cancer	0.00134	0.00639	CcSEcCtD
Amantadine—Cardiac arrest—Fluorouracil—colon cancer	0.00134	0.00637	CcSEcCtD
Amantadine—Ataxia—Fluorouracil—colon cancer	0.00132	0.0063	CcSEcCtD
Amantadine—Urinary incontinence—Capecitabine—colon cancer	0.00131	0.00623	CcSEcCtD
Amantadine—Depressed level of consciousness—Capecitabine—colon cancer	0.00131	0.00623	CcSEcCtD
Amantadine—Sweating increased—Irinotecan—colon cancer	0.00124	0.00589	CcSEcCtD
Amantadine—Neutropenia—Vincristine—colon cancer	0.00122	0.00581	CcSEcCtD
Amantadine—Dysphagia—Fluorouracil—colon cancer	0.00122	0.00579	CcSEcCtD
Amantadine—Photosensitivity reaction—Vincristine—colon cancer	0.00119	0.00567	CcSEcCtD
Amantadine—Neutropenia—Irinotecan—colon cancer	0.00119	0.00565	CcSEcCtD
Amantadine—Mental disability—Capecitabine—colon cancer	0.00118	0.0056	CcSEcCtD
Amantadine—Photosensitivity—Capecitabine—colon cancer	0.00112	0.00533	CcSEcCtD
Amantadine—Photosensitivity reaction—Fluorouracil—colon cancer	0.00111	0.00529	CcSEcCtD
Amantadine—Dysarthria—Methotrexate—colon cancer	0.00107	0.00508	CcSEcCtD
Amantadine—Renal failure acute—Capecitabine—colon cancer	0.00107	0.00507	CcSEcCtD
Amantadine—Libido decreased—Capecitabine—colon cancer	0.00106	0.00505	CcSEcCtD
Amantadine—Amnesia—Capecitabine—colon cancer	0.00105	0.00498	CcSEcCtD
Amantadine—Hallucination—Vincristine—colon cancer	0.00104	0.00494	CcSEcCtD
Amantadine—Urinary tract disorder—Vincristine—colon cancer	0.00103	0.00491	CcSEcCtD
Amantadine—Urethral disorder—Vincristine—colon cancer	0.00102	0.00487	CcSEcCtD
Amantadine—Agranulocytosis—Fluorouracil—colon cancer	0.00101	0.00482	CcSEcCtD
Amantadine—Cardiac failure—Capecitabine—colon cancer	0.00101	0.0048	CcSEcCtD
Amantadine—Lethargy—Capecitabine—colon cancer	0.001	0.00478	CcSEcCtD
Amantadine—Osteoarthritis—Capecitabine—colon cancer	0.000984	0.00468	CcSEcCtD
Amantadine—Visual impairment—Irinotecan—colon cancer	0.00098	0.00466	CcSEcCtD
Amantadine—Disturbance in sexual arousal—Capecitabine—colon cancer	0.000976	0.00465	CcSEcCtD
Amantadine—Depressed level of consciousness—Methotrexate—colon cancer	0.000974	0.00464	CcSEcCtD
Amantadine—Cardiac disorder—Vincristine—colon cancer	0.000969	0.00461	CcSEcCtD
Amantadine—Angiopathy—Vincristine—colon cancer	0.000947	0.00451	CcSEcCtD
Amantadine—Cardiac disorder—Irinotecan—colon cancer	0.000944	0.00449	CcSEcCtD
Amantadine—Mediastinal disorder—Vincristine—colon cancer	0.000941	0.00448	CcSEcCtD
Amantadine—Irritability—Capecitabine—colon cancer	0.000939	0.00447	CcSEcCtD
Amantadine—Cardiac arrest—Capecitabine—colon cancer	0.000935	0.00445	CcSEcCtD
Amantadine—Urinary retention—Capecitabine—colon cancer	0.000935	0.00445	CcSEcCtD
Amantadine—Ataxia—Capecitabine—colon cancer	0.000925	0.0044	CcSEcCtD
Amantadine—Alopecia—Vincristine—colon cancer	0.000922	0.00439	CcSEcCtD
Amantadine—Angiopathy—Irinotecan—colon cancer	0.000922	0.00439	CcSEcCtD
Amantadine—Coma—Methotrexate—colon cancer	0.000922	0.00439	CcSEcCtD
Amantadine—Mediastinal disorder—Irinotecan—colon cancer	0.000916	0.00436	CcSEcCtD
Amantadine—Mental disorder—Vincristine—colon cancer	0.000915	0.00435	CcSEcCtD
Amantadine—Arrhythmia—Irinotecan—colon cancer	0.000908	0.00432	CcSEcCtD
Amantadine—Liver function test abnormal—Capecitabine—colon cancer	0.000908	0.00432	CcSEcCtD
Amantadine—Alopecia—Irinotecan—colon cancer	0.000898	0.00428	CcSEcCtD
Amantadine—Orthostatic hypotension—Capecitabine—colon cancer	0.000898	0.00428	CcSEcCtD
Amantadine—Pulmonary oedema—Methotrexate—colon cancer	0.000898	0.00427	CcSEcCtD
Amantadine—Arrhythmia—Fluorouracil—colon cancer	0.00087	0.00414	CcSEcCtD
Amantadine—Alopecia—Fluorouracil—colon cancer	0.00086	0.0041	CcSEcCtD
Amantadine—Dysphagia—Capecitabine—colon cancer	0.00085	0.00405	CcSEcCtD
Amantadine—Agitation—Vincristine—colon cancer	0.000835	0.00398	CcSEcCtD
Amantadine—Photosensitivity—Methotrexate—colon cancer	0.000834	0.00397	CcSEcCtD
Amantadine—Sweating increased—Capecitabine—colon cancer	0.000828	0.00394	CcSEcCtD
Amantadine—Leukopenia—Vincristine—colon cancer	0.000813	0.00387	CcSEcCtD
Amantadine—Vision blurred—Fluorouracil—colon cancer	0.000799	0.0038	CcSEcCtD
Amantadine—Neutropenia—Capecitabine—colon cancer	0.000795	0.00378	CcSEcCtD
Amantadine—Renal failure acute—Methotrexate—colon cancer	0.000793	0.00378	CcSEcCtD
Amantadine—Leukopenia—Irinotecan—colon cancer	0.000792	0.00377	CcSEcCtD
Amantadine—DDC—embryo—colon cancer	0.000791	0.0989	CbGeAlD
Amantadine—Convulsion—Vincristine—colon cancer	0.000787	0.00375	CcSEcCtD
Amantadine—Hypertension—Vincristine—colon cancer	0.000785	0.00373	CcSEcCtD
Amantadine—Photosensitivity reaction—Capecitabine—colon cancer	0.000776	0.00369	CcSEcCtD
Amantadine—Visual disturbance—Methotrexate—colon cancer	0.000773	0.00368	CcSEcCtD
Amantadine—Hypertension—Irinotecan—colon cancer	0.000764	0.00364	CcSEcCtD
Amantadine—Leukopenia—Fluorouracil—colon cancer	0.000759	0.00361	CcSEcCtD
Amantadine—Lethargy—Methotrexate—colon cancer	0.000747	0.00356	CcSEcCtD
Amantadine—Anaphylactic shock—Vincristine—colon cancer	0.000742	0.00353	CcSEcCtD
Amantadine—Oedema—Vincristine—colon cancer	0.000742	0.00353	CcSEcCtD
Amantadine—Convulsion—Fluorouracil—colon cancer	0.000734	0.0035	CcSEcCtD
Amantadine—Osteoarthritis—Methotrexate—colon cancer	0.000732	0.00349	CcSEcCtD
Amantadine—Confusional state—Irinotecan—colon cancer	0.000728	0.00347	CcSEcCtD
Amantadine—Nervous system disorder—Vincristine—colon cancer	0.000727	0.00346	CcSEcCtD
Amantadine—Oedema—Irinotecan—colon cancer	0.000722	0.00344	CcSEcCtD
Amantadine—Anaphylactic shock—Irinotecan—colon cancer	0.000722	0.00344	CcSEcCtD
Amantadine—Hyperhidrosis—Vincristine—colon cancer	0.000717	0.00341	CcSEcCtD
Amantadine—Nervous system disorder—Irinotecan—colon cancer	0.000708	0.00337	CcSEcCtD
Amantadine—Agranulocytosis—Capecitabine—colon cancer	0.000707	0.00337	CcSEcCtD
Amantadine—Anorexia—Vincristine—colon cancer	0.000707	0.00337	CcSEcCtD
Amantadine—Irritability—Methotrexate—colon cancer	0.000699	0.00333	CcSEcCtD
Amantadine—Hyperhidrosis—Irinotecan—colon cancer	0.000698	0.00332	CcSEcCtD
Amantadine—Confusional state—Fluorouracil—colon cancer	0.000698	0.00332	CcSEcCtD
Amantadine—Hypotension—Vincristine—colon cancer	0.000693	0.0033	CcSEcCtD
Amantadine—Anaphylactic shock—Fluorouracil—colon cancer	0.000692	0.00329	CcSEcCtD
Amantadine—Oedema—Fluorouracil—colon cancer	0.000692	0.00329	CcSEcCtD
Amantadine—Anorexia—Irinotecan—colon cancer	0.000688	0.00328	CcSEcCtD
Amantadine—Ataxia—Methotrexate—colon cancer	0.000688	0.00328	CcSEcCtD
Amantadine—Nervous system disorder—Fluorouracil—colon cancer	0.000678	0.00323	CcSEcCtD
Amantadine—Liver function test abnormal—Methotrexate—colon cancer	0.000676	0.00322	CcSEcCtD
Amantadine—Tachycardia—Fluorouracil—colon cancer	0.000675	0.00321	CcSEcCtD
Amantadine—Hypotension—Irinotecan—colon cancer	0.000675	0.00321	CcSEcCtD
Amantadine—Urinary tract disorder—Capecitabine—colon cancer	0.000672	0.0032	CcSEcCtD
Amantadine—Insomnia—Vincristine—colon cancer	0.000671	0.00319	CcSEcCtD
Amantadine—Oedema peripheral—Capecitabine—colon cancer	0.00067	0.00319	CcSEcCtD
Amantadine—Urethral disorder—Capecitabine—colon cancer	0.000667	0.00318	CcSEcCtD
Amantadine—Paraesthesia—Vincristine—colon cancer	0.000666	0.00317	CcSEcCtD
Amantadine—Anorexia—Fluorouracil—colon cancer	0.000659	0.00314	CcSEcCtD
Amantadine—Visual impairment—Capecitabine—colon cancer	0.000656	0.00312	CcSEcCtD
Amantadine—Insomnia—Irinotecan—colon cancer	0.000653	0.00311	CcSEcCtD
Amantadine—Paraesthesia—Irinotecan—colon cancer	0.000649	0.00309	CcSEcCtD
Amantadine—Hypotension—Fluorouracil—colon cancer	0.000646	0.00308	CcSEcCtD
Amantadine—Decreased appetite—Vincristine—colon cancer	0.000645	0.00307	CcSEcCtD
Amantadine—Dyspnoea—Irinotecan—colon cancer	0.000644	0.00307	CcSEcCtD
Amantadine—Somnolence—Irinotecan—colon cancer	0.000642	0.00306	CcSEcCtD
Amantadine—Gastrointestinal disorder—Vincristine—colon cancer	0.00064	0.00305	CcSEcCtD
Amantadine—Fatigue—Vincristine—colon cancer	0.000639	0.00304	CcSEcCtD
Amantadine—Eye disorder—Capecitabine—colon cancer	0.000636	0.00303	CcSEcCtD
Amantadine—Dyspepsia—Irinotecan—colon cancer	0.000636	0.00303	CcSEcCtD
Amantadine—Constipation—Vincristine—colon cancer	0.000634	0.00302	CcSEcCtD
Amantadine—Cardiac disorder—Capecitabine—colon cancer	0.000631	0.00301	CcSEcCtD
Amantadine—Decreased appetite—Irinotecan—colon cancer	0.000628	0.00299	CcSEcCtD
Amantadine—Insomnia—Fluorouracil—colon cancer	0.000626	0.00298	CcSEcCtD
Amantadine—Gastrointestinal disorder—Irinotecan—colon cancer	0.000624	0.00297	CcSEcCtD
Amantadine—Fatigue—Irinotecan—colon cancer	0.000623	0.00296	CcSEcCtD
Amantadine—Paraesthesia—Fluorouracil—colon cancer	0.000621	0.00296	CcSEcCtD
Amantadine—Constipation—Irinotecan—colon cancer	0.000618	0.00294	CcSEcCtD
Amantadine—Angiopathy—Capecitabine—colon cancer	0.000617	0.00294	CcSEcCtD
Amantadine—Dyspnoea—Fluorouracil—colon cancer	0.000617	0.00294	CcSEcCtD
Amantadine—Somnolence—Fluorouracil—colon cancer	0.000615	0.00293	CcSEcCtD
Amantadine—Mediastinal disorder—Capecitabine—colon cancer	0.000613	0.00292	CcSEcCtD
Amantadine—Dyspepsia—Fluorouracil—colon cancer	0.000609	0.0029	CcSEcCtD
Amantadine—Arrhythmia—Capecitabine—colon cancer	0.000608	0.00289	CcSEcCtD
Amantadine—Decreased appetite—Fluorouracil—colon cancer	0.000601	0.00286	CcSEcCtD
Amantadine—Alopecia—Capecitabine—colon cancer	0.000601	0.00286	CcSEcCtD
Amantadine—DDC—renal system—colon cancer	0.000599	0.0749	CbGeAlD
Amantadine—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000597	0.00284	CcSEcCtD
Amantadine—Mental disorder—Capecitabine—colon cancer	0.000596	0.00284	CcSEcCtD
Amantadine—Feeling abnormal—Irinotecan—colon cancer	0.000595	0.00283	CcSEcCtD
Amantadine—Malnutrition—Capecitabine—colon cancer	0.000592	0.00282	CcSEcCtD
Amantadine—Neutropenia—Methotrexate—colon cancer	0.000592	0.00282	CcSEcCtD
Amantadine—Body temperature increased—Vincristine—colon cancer	0.000586	0.00279	CcSEcCtD
Amantadine—Photosensitivity reaction—Methotrexate—colon cancer	0.000578	0.00275	CcSEcCtD
Amantadine—Body temperature increased—Irinotecan—colon cancer	0.000571	0.00272	CcSEcCtD
Amantadine—Feeling abnormal—Fluorouracil—colon cancer	0.00057	0.00271	CcSEcCtD
Amantadine—Vision blurred—Capecitabine—colon cancer	0.000558	0.00266	CcSEcCtD
Amantadine—Tremor—Capecitabine—colon cancer	0.000555	0.00264	CcSEcCtD
Amantadine—Body temperature increased—Fluorouracil—colon cancer	0.000547	0.0026	CcSEcCtD
Amantadine—Hypersensitivity—Vincristine—colon cancer	0.000546	0.0026	CcSEcCtD
Amantadine—Hypersensitivity—Irinotecan—colon cancer	0.000532	0.00253	CcSEcCtD
Amantadine—Asthenia—Vincristine—colon cancer	0.000532	0.00253	CcSEcCtD
Amantadine—Leukopenia—Capecitabine—colon cancer	0.00053	0.00252	CcSEcCtD
Amantadine—Agranulocytosis—Methotrexate—colon cancer	0.000527	0.00251	CcSEcCtD
Amantadine—Palpitations—Capecitabine—colon cancer	0.000523	0.00249	CcSEcCtD
Amantadine—Asthenia—Irinotecan—colon cancer	0.000518	0.00247	CcSEcCtD
Amantadine—Hypertension—Capecitabine—colon cancer	0.000511	0.00243	CcSEcCtD
Amantadine—Hypersensitivity—Fluorouracil—colon cancer	0.00051	0.00243	CcSEcCtD
Amantadine—Diarrhoea—Vincristine—colon cancer	0.000507	0.00242	CcSEcCtD
Amantadine—Anxiety—Capecitabine—colon cancer	0.000503	0.00239	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000501	0.00238	CcSEcCtD
Amantadine—Urinary tract disorder—Methotrexate—colon cancer	0.0005	0.00238	CcSEcCtD
Amantadine—Urethral disorder—Methotrexate—colon cancer	0.000497	0.00236	CcSEcCtD
Amantadine—Diarrhoea—Irinotecan—colon cancer	0.000494	0.00235	CcSEcCtD
Amantadine—Dry mouth—Capecitabine—colon cancer	0.000493	0.00235	CcSEcCtD
Amantadine—SLC22A2—renal system—colon cancer	0.000493	0.0616	CbGeAlD
Amantadine—Dizziness—Vincristine—colon cancer	0.00049	0.00233	CcSEcCtD
Amantadine—Pruritus—Fluorouracil—colon cancer	0.000489	0.00233	CcSEcCtD
Amantadine—Visual impairment—Methotrexate—colon cancer	0.000488	0.00232	CcSEcCtD
Amantadine—Confusional state—Capecitabine—colon cancer	0.000487	0.00232	CcSEcCtD
Amantadine—Oedema—Capecitabine—colon cancer	0.000483	0.0023	CcSEcCtD
Amantadine—Dizziness—Irinotecan—colon cancer	0.000478	0.00227	CcSEcCtD
Amantadine—Nervous system disorder—Capecitabine—colon cancer	0.000474	0.00226	CcSEcCtD
Amantadine—Eye disorder—Methotrexate—colon cancer	0.000473	0.00225	CcSEcCtD
Amantadine—Diarrhoea—Fluorouracil—colon cancer	0.000473	0.00225	CcSEcCtD
Amantadine—Tachycardia—Capecitabine—colon cancer	0.000472	0.00225	CcSEcCtD
Amantadine—Vomiting—Vincristine—colon cancer	0.000472	0.00224	CcSEcCtD
Amantadine—Cardiac disorder—Methotrexate—colon cancer	0.00047	0.00224	CcSEcCtD
Amantadine—Skin disorder—Capecitabine—colon cancer	0.00047	0.00224	CcSEcCtD
Amantadine—Rash—Vincristine—colon cancer	0.000468	0.00223	CcSEcCtD
Amantadine—Hyperhidrosis—Capecitabine—colon cancer	0.000467	0.00222	CcSEcCtD
Amantadine—Dermatitis—Vincristine—colon cancer	0.000467	0.00222	CcSEcCtD
Amantadine—Headache—Vincristine—colon cancer	0.000465	0.00221	CcSEcCtD
Amantadine—GRIN2A—vagina—colon cancer	0.000464	0.058	CbGeAlD
Amantadine—Anorexia—Capecitabine—colon cancer	0.000461	0.00219	CcSEcCtD
Amantadine—Angiopathy—Methotrexate—colon cancer	0.00046	0.00219	CcSEcCtD
Amantadine—Vomiting—Irinotecan—colon cancer	0.000459	0.00219	CcSEcCtD
Amantadine—Dizziness—Fluorouracil—colon cancer	0.000457	0.00218	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—colon cancer	0.000457	0.00217	CcSEcCtD
Amantadine—Rash—Irinotecan—colon cancer	0.000455	0.00217	CcSEcCtD
Amantadine—Dermatitis—Irinotecan—colon cancer	0.000455	0.00217	CcSEcCtD
Amantadine—Headache—Irinotecan—colon cancer	0.000452	0.00215	CcSEcCtD
Amantadine—Hypotension—Capecitabine—colon cancer	0.000452	0.00215	CcSEcCtD
Amantadine—Alopecia—Methotrexate—colon cancer	0.000448	0.00213	CcSEcCtD
Amantadine—Mental disorder—Methotrexate—colon cancer	0.000444	0.00211	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—colon cancer	0.000441	0.0021	CcSEcCtD
Amantadine—Nausea—Vincristine—colon cancer	0.000441	0.0021	CcSEcCtD
Amantadine—Vomiting—Fluorouracil—colon cancer	0.00044	0.00209	CcSEcCtD
Amantadine—Insomnia—Capecitabine—colon cancer	0.000437	0.00208	CcSEcCtD
Amantadine—Rash—Fluorouracil—colon cancer	0.000436	0.00208	CcSEcCtD
Amantadine—Dermatitis—Fluorouracil—colon cancer	0.000436	0.00207	CcSEcCtD
Amantadine—Paraesthesia—Capecitabine—colon cancer	0.000434	0.00207	CcSEcCtD
Amantadine—Headache—Fluorouracil—colon cancer	0.000433	0.00206	CcSEcCtD
Amantadine—Dyspnoea—Capecitabine—colon cancer	0.000431	0.00205	CcSEcCtD
Amantadine—Nausea—Irinotecan—colon cancer	0.000429	0.00204	CcSEcCtD
Amantadine—DDC—Metabolism—CA7—colon cancer	0.000427	0.00597	CbGpPWpGaD
Amantadine—Dyspepsia—Capecitabine—colon cancer	0.000426	0.00203	CcSEcCtD
Amantadine—Decreased appetite—Capecitabine—colon cancer	0.00042	0.002	CcSEcCtD
Amantadine—GRIN2A—Post NMDA receptor activation events—HRAS—colon cancer	0.00042	0.00586	CbGpPWpGaD
Amantadine—Gastrointestinal disorder—Capecitabine—colon cancer	0.000417	0.00199	CcSEcCtD
Amantadine—Fatigue—Capecitabine—colon cancer	0.000417	0.00198	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—colon cancer	0.000416	0.00198	CcSEcCtD
Amantadine—Constipation—Capecitabine—colon cancer	0.000413	0.00197	CcSEcCtD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000412	0.00576	CbGpPWpGaD
Amantadine—Nausea—Fluorouracil—colon cancer	0.000411	0.00196	CcSEcCtD
Amantadine—MAOB—embryo—colon cancer	0.000407	0.0509	CbGeAlD
Amantadine—SLC22A2—digestive system—colon cancer	0.000404	0.0506	CbGeAlD
Amantadine—GRIN2B—ErbB4 signaling events—PIK3CA—colon cancer	0.000403	0.00563	CbGpPWpGaD
Amantadine—Feeling abnormal—Capecitabine—colon cancer	0.000398	0.0019	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—colon cancer	0.000395	0.00188	CcSEcCtD
Amantadine—GRIN1—Axon guidance—DCC—colon cancer	0.000394	0.00551	CbGpPWpGaD
Amantadine—GRIN2B—Reelin signaling pathway—AKT1—colon cancer	0.000394	0.0055	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TOP1—colon cancer	0.000388	0.00543	CbGpPWpGaD
Amantadine—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000387	0.0054	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—DCC—colon cancer	0.000384	0.00537	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000383	0.00536	CbGpPWpGaD
Amantadine—Body temperature increased—Capecitabine—colon cancer	0.000382	0.00182	CcSEcCtD
Amantadine—Convulsion—Methotrexate—colon cancer	0.000382	0.00182	CcSEcCtD
Amantadine—GRIN2A—Alzheimers Disease—CASP3—colon cancer	0.000373	0.00521	CbGpPWpGaD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000373	0.00177	CcSEcCtD
Amantadine—GRIN1—Post NMDA receptor activation events—HRAS—colon cancer	0.000366	0.00511	CbGpPWpGaD
Amantadine—DDC—liver—colon cancer	0.000366	0.0457	CbGeAlD
Amantadine—Confusional state—Methotrexate—colon cancer	0.000363	0.00173	CcSEcCtD
Amantadine—Anaphylactic shock—Methotrexate—colon cancer	0.00036	0.00171	CcSEcCtD
Amantadine—MAOB—Metabolism—CA7—colon cancer	0.00036	0.00502	CbGpPWpGaD
Amantadine—GRIN2B—Post NMDA receptor activation events—HRAS—colon cancer	0.000357	0.00499	CbGpPWpGaD
Amantadine—Hypersensitivity—Capecitabine—colon cancer	0.000356	0.0017	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—colon cancer	0.000353	0.00168	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—colon cancer	0.00035	0.00166	CcSEcCtD
Amantadine—SLC22A1—renal system—colon cancer	0.000348	0.0435	CbGeAlD
Amantadine—Hyperhidrosis—Methotrexate—colon cancer	0.000348	0.00166	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—TYMS—colon cancer	0.000347	0.00485	CbGpPWpGaD
Amantadine—Asthenia—Capecitabine—colon cancer	0.000347	0.00165	CcSEcCtD
Amantadine—Anorexia—Methotrexate—colon cancer	0.000343	0.00163	CcSEcCtD
Amantadine—Pruritus—Capecitabine—colon cancer	0.000342	0.00163	CcSEcCtD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—colon cancer	0.000337	0.00471	CbGpPWpGaD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000337	0.00471	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000337	0.0047	CbGpPWpGaD
Amantadine—Hypotension—Methotrexate—colon cancer	0.000336	0.0016	CcSEcCtD
Amantadine—SIGMAR1—smooth muscle tissue—colon cancer	0.000334	0.0418	CbGeAlD
Amantadine—Diarrhoea—Capecitabine—colon cancer	0.000331	0.00157	CcSEcCtD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000329	0.00459	CbGpPWpGaD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—colon cancer	0.000329	0.00459	CbGpPWpGaD
Amantadine—Insomnia—Methotrexate—colon cancer	0.000325	0.00155	CcSEcCtD
Amantadine—GRIN1—Alzheimers Disease—CASP3—colon cancer	0.000325	0.00455	CbGpPWpGaD
Amantadine—Paraesthesia—Methotrexate—colon cancer	0.000323	0.00154	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—colon cancer	0.000321	0.00153	CcSEcCtD
Amantadine—Somnolence—Methotrexate—colon cancer	0.00032	0.00152	CcSEcCtD
Amantadine—Dizziness—Capecitabine—colon cancer	0.00032	0.00152	CcSEcCtD
Amantadine—GRIN2B—Alzheimers Disease—CASP3—colon cancer	0.000317	0.00443	CbGpPWpGaD
Amantadine—Dyspepsia—Methotrexate—colon cancer	0.000317	0.00151	CcSEcCtD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000315	0.0044	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TP53—colon cancer	0.000313	0.00438	CbGpPWpGaD
Amantadine—Decreased appetite—Methotrexate—colon cancer	0.000313	0.00149	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—colon cancer	0.000311	0.00148	CcSEcCtD
Amantadine—Fatigue—Methotrexate—colon cancer	0.00031	0.00148	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—BRAF—colon cancer	0.00031	0.00433	CbGpPWpGaD
Amantadine—MAOB—renal system—colon cancer	0.000308	0.0385	CbGeAlD
Amantadine—Vomiting—Capecitabine—colon cancer	0.000307	0.00146	CcSEcCtD
Amantadine—Rash—Capecitabine—colon cancer	0.000305	0.00145	CcSEcCtD
Amantadine—Dermatitis—Capecitabine—colon cancer	0.000305	0.00145	CcSEcCtD
Amantadine—Headache—Capecitabine—colon cancer	0.000303	0.00144	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—colon cancer	0.000297	0.00141	CcSEcCtD
Amantadine—GRIN2D—Alzheimers Disease—TP53—colon cancer	0.000291	0.00407	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—BRAF—colon cancer	0.000288	0.00403	CbGpPWpGaD
Amantadine—Nausea—Capecitabine—colon cancer	0.000287	0.00137	CcSEcCtD
Amantadine—GRIN1—BDNF signaling pathway—APC—colon cancer	0.000286	0.00399	CbGpPWpGaD
Amantadine—Body temperature increased—Methotrexate—colon cancer	0.000284	0.00135	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—DCC—colon cancer	0.000281	0.00393	CbGpPWpGaD
Amantadine—DDC—lymph node—colon cancer	0.00028	0.0351	CbGeAlD
Amantadine—GRIN2B—BDNF signaling pathway—APC—colon cancer	0.000278	0.00389	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000275	0.00384	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—DCC—colon cancer	0.000274	0.00383	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000268	0.00374	CbGpPWpGaD
Amantadine—Hypersensitivity—Methotrexate—colon cancer	0.000265	0.00126	CcSEcCtD
Amantadine—DDC—Metabolism—ODC1—colon cancer	0.000259	0.00362	CbGpPWpGaD
Amantadine—DDC—Metabolism—CHST5—colon cancer	0.000259	0.00362	CbGpPWpGaD
Amantadine—Asthenia—Methotrexate—colon cancer	0.000258	0.00123	CcSEcCtD
Amantadine—Pruritus—Methotrexate—colon cancer	0.000255	0.00121	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—PTGS2—colon cancer	0.000254	0.00355	CbGpPWpGaD
Amantadine—MAOB—digestive system—colon cancer	0.000253	0.0316	CbGeAlD
Amantadine—SLC22A1—vagina—colon cancer	0.000252	0.0315	CbGeAlD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.00025	0.0035	CbGpPWpGaD
Amantadine—ABCB1—blood vessel—colon cancer	0.000249	0.0311	CbGeAlD
Amantadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000248	0.00347	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—SRC—colon cancer	0.000247	0.00345	CbGpPWpGaD
Amantadine—Diarrhoea—Methotrexate—colon cancer	0.000246	0.00117	CcSEcCtD
Amantadine—DDC—Circadian rythm related genes—PPARG—colon cancer	0.000246	0.00343	CbGpPWpGaD
Amantadine—SIGMAR1—bone marrow—colon cancer	0.000243	0.0304	CbGeAlD
Amantadine—GRIN2B—EPH-Ephrin signaling—SRC—colon cancer	0.000241	0.00336	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—VEGFA—colon cancer	0.00024	0.00336	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—TP53—colon cancer	0.000239	0.00334	CbGpPWpGaD
Amantadine—Dizziness—Methotrexate—colon cancer	0.000238	0.00113	CcSEcCtD
Amantadine—GRIN2C—Neuronal System—BRAF—colon cancer	0.000238	0.00332	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HNF4A—colon cancer	0.000237	0.00331	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—BRAF—colon cancer	0.000237	0.00331	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CASP3—colon cancer	0.000236	0.0033	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—VEGFA—colon cancer	0.000234	0.00327	CbGpPWpGaD
Amantadine—SIGMAR1—vagina—colon cancer	0.000233	0.0291	CbGeAlD
Amantadine—GRIN2B—Developmental Biology—HNF4A—colon cancer	0.000231	0.00322	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CCND1—colon cancer	0.00023	0.00321	CbGpPWpGaD
Amantadine—Vomiting—Methotrexate—colon cancer	0.000229	0.00109	CcSEcCtD
Amantadine—Rash—Methotrexate—colon cancer	0.000227	0.00108	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—colon cancer	0.000227	0.00108	CcSEcCtD
Amantadine—Headache—Methotrexate—colon cancer	0.000225	0.00107	CcSEcCtD
Amantadine—MAOB—vagina—colon cancer	0.000223	0.0279	CbGeAlD
Amantadine—GRIN2D—Neuronal System—BRAF—colon cancer	0.000221	0.00308	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—CASP3—colon cancer	0.00022	0.00307	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CHST5—colon cancer	0.000218	0.00304	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ODC1—colon cancer	0.000218	0.00304	CbGpPWpGaD
Amantadine—Nausea—Methotrexate—colon cancer	0.000214	0.00102	CcSEcCtD
Amantadine—SLC22A1—liver—colon cancer	0.000213	0.0266	CbGeAlD
Amantadine—DDC—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000212	0.00296	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TP53—colon cancer	0.000209	0.00291	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—BRAF—colon cancer	0.000206	0.00288	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—TP53—colon cancer	0.000203	0.00284	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—CASP3—colon cancer	0.000201	0.00281	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—BRAF—colon cancer	0.000201	0.00281	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—EP300—colon cancer	0.000197	0.00275	CbGpPWpGaD
Amantadine—SIGMAR1—liver—colon cancer	0.000197	0.0246	CbGeAlD
Amantadine—GRIN2B—BDNF signaling pathway—CASP3—colon cancer	0.000196	0.00274	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—CTNNB1—colon cancer	0.000194	0.00271	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CA7—colon cancer	0.000191	0.00267	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.00019	0.00265	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—CTNNB1—colon cancer	0.000189	0.00264	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000189	0.00264	CbGpPWpGaD
Amantadine—MAOB—liver—colon cancer	0.000188	0.0235	CbGeAlD
Amantadine—DDC—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000187	0.00261	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MYC—colon cancer	0.000184	0.00257	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TGFB1—colon cancer	0.000184	0.00257	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000182	0.00254	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—BRAF—colon cancer	0.000181	0.00253	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—EGFR—colon cancer	0.00018	0.00252	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CA7—colon cancer	0.000178	0.00249	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000176	0.00246	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—SRC—colon cancer	0.000175	0.00245	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—colon cancer	0.000174	0.00243	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—SRC—colon cancer	0.000171	0.00239	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000171	0.00239	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—colon cancer	0.000169	0.00236	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—EP300—colon cancer	0.000169	0.00236	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—EP300—colon cancer	0.000161	0.00225	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.00016	0.00224	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—BRAF—colon cancer	0.000158	0.00221	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—BRAF—colon cancer	0.000154	0.00215	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—colon cancer	0.000151	0.00211	CbGpPWpGaD
Amantadine—SIGMAR1—lymph node—colon cancer	0.000151	0.0188	CbGeAlD
Amantadine—ABCB1—embryo—colon cancer	0.000148	0.0186	CbGeAlD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000145	0.00202	CbGpPWpGaD
Amantadine—MAOB—lymph node—colon cancer	0.000144	0.018	CbGeAlD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000144	0.00201	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—colon cancer	0.000143	0.00199	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TYMS—colon cancer	0.000137	0.00191	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—colon cancer	0.000133	0.00185	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000126	0.00176	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—colon cancer	0.000123	0.00172	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000123	0.00172	CbGpPWpGaD
Amantadine—ABCB1—epithelium—colon cancer	0.000121	0.0151	CbGeAlD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—colon cancer	0.00012	0.00168	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ODC1—colon cancer	0.000116	0.00162	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CHST5—colon cancer	0.000116	0.00162	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—colon cancer	0.000115	0.00161	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000115	0.00161	CbGpPWpGaD
Amantadine—ABCB1—renal system—colon cancer	0.000112	0.014	CbGeAlD
Amantadine—GRIN2C—Neuronal System—HRAS—colon cancer	0.000109	0.00153	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—AKT1—colon cancer	0.000109	0.00152	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—colon cancer	0.000109	0.00152	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ODC1—colon cancer	0.000108	0.00151	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CHST5—colon cancer	0.000108	0.00151	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—BRAF—colon cancer	0.000107	0.0015	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—AKT1—colon cancer	0.000106	0.00148	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	0.000106	0.00148	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CA7—colon cancer	0.000104	0.00146	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—PPARG—colon cancer	0.000103	0.00144	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—colon cancer	0.000102	0.00142	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—PPARG—colon cancer	0.0001	0.0014	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—BRAF—colon cancer	0.0001	0.0014	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PPARG—colon cancer	9.69e-05	0.00135	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	9.56e-05	0.00134	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—colon cancer	9.49e-05	0.00133	CbGpPWpGaD
Amantadine—ABCB1—lymphoid tissue—colon cancer	9.33e-05	0.0117	CbGeAlD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—colon cancer	9.25e-05	0.00129	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CASP3—colon cancer	9.24e-05	0.00129	CbGpPWpGaD
Amantadine—ABCB1—digestive system—colon cancer	9.21e-05	0.0115	CbGeAlD
Amantadine—GRIN1—Axon guidance—SRC—colon cancer	9.17e-05	0.00128	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DLC1—colon cancer	9.08e-05	0.00127	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	9.06e-05	0.00127	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—SRC—colon cancer	8.94e-05	0.00125	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—VEGFA—colon cancer	8.93e-05	0.00125	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—colon cancer	8.82e-05	0.00123	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	8.82e-05	0.00123	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—VEGFA—colon cancer	8.7e-05	0.00122	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—colon cancer	8.6e-05	0.0012	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LGR5—colon cancer	8.53e-05	0.00119	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	8.49e-05	0.00119	CbGpPWpGaD
Amantadine—ABCB1—bone marrow—colon cancer	8.49e-05	0.0106	CbGeAlD
Amantadine—GRIN2A—Neuronal System—HRAS—colon cancer	8.34e-05	0.00116	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—BRAF—colon cancer	8.22e-05	0.00115	CbGpPWpGaD
Amantadine—ABCB1—vagina—colon cancer	8.13e-05	0.0102	CbGeAlD
Amantadine—GRIN1—Axon guidance—EGFR—colon cancer	8.04e-05	0.00112	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—VEGFA—colon cancer	7.84e-05	0.0011	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—colon cancer	7.83e-05	0.00109	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—BRAF—colon cancer	7.66e-05	0.00107	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—colon cancer	7.59e-05	0.00106	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—colon cancer	7.4e-05	0.00103	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—colon cancer	7.27e-05	0.00102	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CTNNB1—colon cancer	7.24e-05	0.00101	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TGFB1—colon cancer	7.2e-05	0.00101	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—colon cancer	7.09e-05	0.00099	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CTNNB1—colon cancer	7.06e-05	0.000986	CbGpPWpGaD
Amantadine—ABCB1—liver—colon cancer	6.86e-05	0.00858	CbGeAlD
Amantadine—DDC—Metabolism—ABCB1—colon cancer	6.84e-05	0.000956	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EP300—colon cancer	6.73e-05	0.00094	CbGpPWpGaD
Amantadine—DDC—Metabolism—TYMS—colon cancer	6.72e-05	0.000939	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EP300—colon cancer	6.56e-05	0.000916	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—SRC—colon cancer	6.54e-05	0.000914	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ABCB1—colon cancer	6.53e-05	0.000911	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	6.47e-05	0.000904	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—colon cancer	6.45e-05	0.000901	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—SRC—colon cancer	6.38e-05	0.000891	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VEGFA—colon cancer	6.37e-05	0.00089	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—EP300—colon cancer	6.34e-05	0.000885	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CHST5—colon cancer	6.32e-05	0.000883	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ODC1—colon cancer	6.32e-05	0.000883	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—colon cancer	6.29e-05	0.000879	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—colon cancer	6.29e-05	0.000879	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VEGFA—colon cancer	6.21e-05	0.000868	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—colon cancer	6.14e-05	0.000857	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AXIN2—colon cancer	6.13e-05	0.000856	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ABCB1—colon cancer	6.08e-05	0.00085	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TGFB1—colon cancer	5.85e-05	0.000817	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	5.78e-05	0.000807	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ABCB1—colon cancer	5.76e-05	0.000804	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—colon cancer	5.73e-05	0.000801	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TGFB1—colon cancer	5.7e-05	0.000796	CbGpPWpGaD
Amantadine—MAOB—Metabolism—TYMS—colon cancer	5.66e-05	0.00079	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—colon cancer	5.59e-05	0.000781	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—colon cancer	5.42e-05	0.000757	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—colon cancer	5.28e-05	0.000738	CbGpPWpGaD
Amantadine—ABCB1—lymph node—colon cancer	5.26e-05	0.00658	CbGeAlD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—colon cancer	4.93e-05	0.000689	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	4.91e-05	0.000686	CbGpPWpGaD
Amantadine—DDC—Metabolism—PPARG—colon cancer	4.76e-05	0.000665	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—colon cancer	4.6e-05	0.000643	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—colon cancer	4.6e-05	0.000642	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	4.56e-05	0.000637	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—colon cancer	4.54e-05	0.000634	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—colon cancer	4.49e-05	0.000627	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	4.44e-05	0.00062	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	4.4e-05	0.000614	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	4.3e-05	0.0006	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	4.09e-05	0.000571	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—colon cancer	4.07e-05	0.000568	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PPARG—colon cancer	4.01e-05	0.00056	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.97e-05	0.000555	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—colon cancer	3.96e-05	0.000554	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.87e-05	0.000541	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—colon cancer	3.78e-05	0.000528	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—colon cancer	3.74e-05	0.000523	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.56e-05	0.000497	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.55e-05	0.000496	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—colon cancer	3.52e-05	0.000492	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.48e-05	0.000487	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.29e-05	0.00046	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—colon cancer	3.15e-05	0.00044	CbGpPWpGaD
Amantadine—DDC—Metabolism—EP300—colon cancer	3.11e-05	0.000435	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCB1—colon cancer	3.06e-05	0.000427	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	3.02e-05	0.000422	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMS—colon cancer	3e-05	0.000419	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.92e-05	0.000409	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCB1—colon cancer	2.85e-05	0.000398	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMS—colon cancer	2.8e-05	0.000391	CbGpPWpGaD
Amantadine—MAOB—Metabolism—EP300—colon cancer	2.62e-05	0.000366	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.47e-05	0.000345	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—colon cancer	2.3e-05	0.000322	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARG—colon cancer	2.13e-05	0.000297	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARG—colon cancer	1.98e-05	0.000277	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—colon cancer	1.94e-05	0.000271	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—colon cancer	1.88e-05	0.000263	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR3—colon cancer	1.77e-05	0.000247	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—colon cancer	1.67e-05	0.000234	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMS—colon cancer	1.64e-05	0.000229	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APC—colon cancer	1.63e-05	0.000227	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—colon cancer	1.63e-05	0.000227	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—colon cancer	1.58e-05	0.000221	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—colon cancer	1.56e-05	0.000218	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—colon cancer	1.53e-05	0.000213	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—colon cancer	1.48e-05	0.000207	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—colon cancer	1.42e-05	0.000198	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—colon cancer	1.4e-05	0.000195	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—EP300—colon cancer	1.39e-05	0.000194	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—EP300—colon cancer	1.3e-05	0.000181	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—colon cancer	1.29e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—colon cancer	1.19e-05	0.000166	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARG—colon cancer	1.16e-05	0.000162	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—colon cancer	1.16e-05	0.000162	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—colon cancer	1.15e-05	0.00016	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—colon cancer	1.12e-05	0.000156	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNB1—colon cancer	1.1e-05	0.000154	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1A—colon cancer	1.08e-05	0.000151	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—colon cancer	1.05e-05	0.000147	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—colon cancer	1.03e-05	0.000144	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EP300—colon cancer	1.03e-05	0.000143	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SRC—colon cancer	9.98e-06	0.000139	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—colon cancer	9.72e-06	0.000136	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—colon cancer	9.6e-06	0.000134	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—colon cancer	9.59e-06	0.000134	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—colon cancer	9.14e-06	0.000128	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—colon cancer	8.95e-06	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFB1—colon cancer	8.92e-06	0.000125	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—colon cancer	8.75e-06	0.000122	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—colon cancer	8.41e-06	0.000117	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—colon cancer	8.27e-06	0.000115	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—colon cancer	7.84e-06	0.000109	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—EP300—colon cancer	7.6e-06	0.000106	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—colon cancer	7.59e-06	0.000106	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—colon cancer	7.35e-06	0.000103	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—colon cancer	7.03e-06	9.81e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—colon cancer	6.2e-06	8.67e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—colon cancer	5.62e-06	7.85e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—colon cancer	4.59e-06	6.42e-05	CbGpPWpGaD
